Lubricin

Lubricin (also known as proteoglycan 4 or PRG4) is a surface-active mucinous glycoprotein that serves as the primary boundary lubricant in synovial joints. It is encoded by the PRG4 gene and secreted by superficial zone cells of articular cartilage and synoviocytes.

Lubricin provides boundary lubrication by coating the cartilage surface, enabling near-frictionless joint motion and preventing cell and protein adhesion. Its lubricating function depends critically on extensive O-linked glycosylation within its mucin-rich domain. Beyond lubrication, lubricin plays multiple protective roles: it prevents chondrocyte apoptosis in superficial cartilage layers, modulates superficial zone cell differentiation to maintain cartilage homeostasis, and regulates inflammatory responses by binding to and antagonizing Toll-like receptors 2 and 4. The protein also interacts with cartilage matrix proteins including COMP, fibronectin, and collagen II to anchor itself to the cartilage surface, and forms crosslinks with galectin-3 that reinforce the lubricating boundary layer.

Lubricin is considered an exerkine, as its expression increases with joint movement and exercise. The evidence supporting this classification includes the observation that lubricin synthesis is triggered by mechanical loading and joint motion. In the context of osteoarthritis prevention and treatment, lubricin functions alongside other exercise-induced molecules like irisin, with both contributing to cartilage homeostasis in response to physical activity. This exercise-responsive secretion pattern aligns with the defining characteristic of exerkines as molecules whose production is stimulated by physical activity.

Osteoarthritis Treatment: Recombinant lubricin supplementation has shown chondroprotective effects in animal models of osteoarthritis. In ovariectomized rats, both early and late treatment with recombinant lubricin attenuated OA progression by protecting articular cartilage from degeneration, reducing proteoglycan loss, normalizing subchondral bone remodeling, and inhibiting vascular invasion from subchondral bone to calcified cartilage. PMID 25576671

In a rat anterior cruciate ligament transection model, specific lubricin mimetics improved femoral articular cartilage degeneration scores and reduced osteophyte formation without inciting additional synovial inflammation. PMID 32004084 A systematic review of lubricin supplementation studies found that all 15 papers describing intra-articular lubricin administration reported beneficial effects. PMID 32504786

Mechanism of Chondroprotection: Lubricin prevents chondrocyte apoptosis through boundary lubrication. Studies demonstrate a direct correlation between coefficient of friction and chondrocyte death in superficial cartilage layers, with lubricin supplementation significantly lowering both friction and apoptotic cell numbers. PMID 23530215 This suggests that restoring boundary lubrication may prevent cartilage deterioration in patients with genetic or acquired lubricin deficiency. PMID 23530215

Anti-Inflammatory Properties: Lubricin binds to and regulates Toll-like receptors (TLRs), modulating inflammatory responses. In vitro studies show lubricin acts as an antagonist of TLR2 and TLR4, halting downstream inflammatory processes and preventing cytokine release. PMID 26752378PMID 31733682 In a rat OA model, intra-articular lubricin injections inhibited systemic inflammatory signaling and reduced pain. PMID 26752378

Additional Therapeutic Applications: Lubricin has been evaluated for dry eye disease, where full-length recombinant human PRG4 (rhPRG4) demonstrated clinical efficacy in improving signs and symptoms, with in vitro studies showing reduced inflammation-induced cytokine production and MMP-9 inhibition. PMID 37678729 The protein has also been investigated as a potential therapeutic and biomarker in sepsis due to its anti-inflammatory properties. PMID 31733682